263 Great Valley Parkway
Malvern, PA 19355
484 328 4701
Empleados a tiempo completo: 84
|Nombre||Título||Paga||Ejecutado||Año de nacimiento|
|Dr. Shankar Musunuri M.B.A., MBA, Ph.D.||Co-Founder, Chairman & CEO||1,2M||1,26M||1964|
|Dr. Uday B. Kompella Ph.D.||Co-founder & Independent Director||56,72k||N/A||1967|
|Mr. Quan Anh Vu||CFO, Chief Bus. Officer & Principal Accounting Officer||N/A||N/A||1973|
|Dr. Arun Upadhyay Ph.D.||Chief Scientific Officer and Head of Research, Devel. & Medical||N/A||N/A||1982|
|Ms. Tiffany J. Hamilton M.B.A.||Head of Corp. Communications||N/A||N/A||N/A|
|Ms. Zara Gaudioso||AVP, Head of HR & Chief of Staff||N/A||N/A||N/A|
|Mr. Michael Shine M.B.A.||Sr. VP of Commercial||N/A||N/A||N/A|
|Ms. Jyothy Pillai M.S.||Head of Regulatory & Quality||N/A||N/A||N/A|
|Dr. Huma Qamar CMI, M.D., M.P.H.||Head of Clinical Devel. & Medical Affairs||N/A||N/A||N/A|
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
El ISS Governance QualityScore de Ocugen, Inc., a día 30 de mayo de 2023, es 7. Las puntuaciones base son Auditoría: 7; Tablero: 7; Derechos de los accionistas: 8; Compensación: 6.